Krenkel O, et al. - This study was performed to clarify the therapeutic effects of inhibiting monocyte infiltration in nonalcoholic steatohepatitis (NASH) models by using cenicriviroc (CVC), an oral dual chemokine receptor CCR2/CCR5 antagonist that was under clinical evaluation. The authors revealed that pharmacological inhibition of CCR2+ monocyte recruitment efficiently ameliorated insulin resistance, hepatic inflammation, and fibrosis, supporting the therapeutic potential of CVC in patients with NASH.